BANZEL
As listed in the register: BANZEL
200 mg · tablet
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Rufinamide
- Made by
- Eisai Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Rufinamide). It describes the substance, not this exact product.
The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown.
The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel.
Rufinamide is extensively metabolized but has no active metabolites.
Food increased the extent of absorption of rufinamide in healthy volunteers by 34% and increased peak exposure by 56% after a single dose of 400 mg tablet, although the T max was not elevated [see Dosage and Administration (2.2) ].
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-04
Safety of the active substance
From the US prescribing label for the same active substance (Rufinamide). It describes the substance, not this exact product.
- Rufinamide is contraindicated in patients with Familial Short QT syndrome [see Warnings and Precautions (5.3) ].
The most common (≥3%) adverse reactions with an incidence greater than in placebo for rufinamide were somnolence, vomiting, and headache.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States7 matching products
European UnionNo exact match for this strength and form
Spain1 matching products
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Eisai Limited |
|---|---|
| Active substance | Rufinamide |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 200 mg |
| Form | tablet |
| Classification | N03AF03 · Pain, sleep, mood, epilepsy and the brain |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02369621 |
| DPD drug code | 85455 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.